Psychiatr Pol
-
Presentation of the difficulties in diagnosing Münchausen syndrome by proxy. ⋯ In appointing the expert, the art. 196 of the Code of Criminal Procedure should be considered, which states that the expert should not be the treating doctor, because his opinion loses value impartiality. Diagnosis of Münchausen Syndrome by proxy itself stirs up numerous controversies..
-
In spite of the progress in medicine post operative cognitive deficiency (POCD) remains an important clinical problem. Since the introduction of cardiac surgery there have been frequent reports of its adverse neurological outcomes. Recent technological advances have contributed to a lesser occurrence of clinically evident complications such as coma, stroke, epilepsy or blindness. ⋯ There are, however, patients who suffer from persisting POCD. Modern medicine has not developed standards for treatment of this complication. Setting up methods for prevention, detection and treatment of POCD should be the concern of both physicians and researchers in the following years.
-
The aim of the study was to assess efficacy and safety of electroconvulsive therapy. ⋯ Electroconvulsive procedures were safe and effective. Electroconvulsive treatment was most effective in catatonic patients with schizophrenia and in depressive patients with bipolar disorder.
-
To assess cultural attitudes and beliefs among (female) patients being treated for various kinds of eating disorders in comparison with (female) patients diagnosed with depression and healthy girls. ⋯ The obtained results may indicate the greater significance of cultural mechanisms in bulimia than anorexia nervosa. They may also be an expression of the limited possibility of introspection of girls with a diagnosis of restrictive anorexia. A negative perception of femininity in the family and culture accompanies not only eating disorders, but also depressive disorders.
-
Clinical practice and data from literature indicate that up to 30% of the patients suffering from depression meet criteria for treatment-resistant depression. In the past decade, interest in the use of NMDA receptor modulators in the treatment of treatment-resistant depression is increasing. The use of ketamine--an noncompetitive antagonist of the NMDA receptors, allows some patients suffering from treatment resistant depression to achieve rapid and significant improvement. ⋯ Neurobiological basis of the glutaminergic pathways and the postulated role of glutamate in mood modulation have been described, as well as possible adverse events associated with ketamine infusion. Concerns relate to the optimal dosage, frequency of administration, long-term safety and efficacy of the therapy. Interesting results of the published articles encourage further studies on therapeutic use of NMDA receptor modulators in the treatment of treatment-resistant depression.